# Regulation (EU) No 1238/2010 of the European Parliament and of the Council of 15 December 2010 amending Annex I to Council Regulation (EEC) No 2658/87 as regards the provision of duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals, Annex IV

Extent: E+W+S+N.I.

List of pharmaceutical intermediates, i.e. compounds used for the manufacture of finished pharmaceutical products, to be withdrawn from the list of products receiving duty-free treatment included in Annex 6 to Annex I to Regulation (EEC) No 2658/87 due to their transfer to the list of products receiving duty-free treatment included in Annex 3 to Annex I to Regulation (EEC) No 2658/87
CN code
CAS RN
Name
2915 39 00
2937 29 00
7753-60-8
17-alpha-hydroxy-3,20-dioxopregna-4,9(11)-diene-21-yl acetate
see anecortave (INN)
2920 90 85
163133-43-5
4-(nitrooxy)butyl (2S)-2-(6-methoxy-2-naphthyl) propanoate
see naproxcinod (INN)
2924 29 98
194085-75-1
2-(2-chlorophenyl)-2-hydroxyethyl carbamate
see carisbamate (INN)
2933 39 99
103129-82-4
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
see levamlodipine (INN)
2933 39 99
319460-85-0
N-methyl-2-{[3-((E)-2-pyridin-2-ylvinyl)-1H-indazol-6-yl]sulfanyl}benzamide
see axitinib (INN)
2934 10 00
302962-49-8
N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)thiazole-5-carboxamide
see dasatinib (INN)
2934 99 90
143491-57-0
(2R,5S)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
see emtricitabine(INN)
2934 99 90
98819-76-2
(2S)-2-[(S)-(2-ethoxyphenoxy)phenylmethyl]morpholine
see esreboxetine (INN)
2934 99 90
475479-34-6
(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid
see aleglitazar (INN)
2934 99 90
377727-87-2
2-(2-furyl)-7-(2-{4-[4-(2-methoxyethoxy)phenyl] piperazin-1-yl}ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[2,3-c]pyrimidin-5-amine
see preladenant (INN)
2934 99 90
189003-92-7
2-{7-fluoro-2-oxo-4-[2-(4-thieno[3,2-c]pyridin-4-ylpiperazin-1-yl)ethyl]quinolin-1(2H)-yl}acetamide
see trelanserin (INN)
2934 99 90
134379-77-4
4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1H)-one
see dexelvucitabine (INN)
2934 99 90
518048-05-0
potassium 4-[N-(2-fluorobenzyl)carbamoyl]-1-methyl-2-[1-methyl-1-(5-methyl-1,3,4-oxadiazole-2-carboxamido)ethyl]-6-oxo-1,6-dihydropyrimidine-5-olate
see raltegravir (INN)
2935 00 90
170569-88-7
4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzene-1-sulfonamide
see mavacoxib (INN)
2935 00 90
186497-07-4
N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
see zibotentan (INN)

---
Source: https://www.legislation.gov.uk/eur/2010/1238/annex/IV (the official version)
Page: https://openlegislation.uk/eu-regulation-2010-1238/annex-IV
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.